About the Event
QSAM Biosciences (OTCQB: QSAM) is a clinical-stage radiopharmaceutical company that is developing a next generation treatment for metastatic bone cancer and primary bone cancers such as osteosarcoma and Ewings Sarcoma. The FDA has cleared an IND for their lead asset, CycloSam®, to address the $20B bone mets market and a phase 1 trial is expected to be completed later this year.
CycloSam has also been granted Orphan Drug and Rare Pediatric Disease designations by the FDA for osteosarcoma. QSAM expects to hit several important milestones and value inflection points in the next 24-months, and the company will look to apply this platform technology to other large indications in the coming years.
Join this webinar to hear QSAM CEO, Douglas Baum and
Justin Walsh PhD, Health Analyst for Jones Trading discuss their derisked treatment for the $20B bone cancer market.